Contact
searchSearch
HMP Global
Jasmin Hundal, MD, DipABLM, MS, MPH
Conference Coverage
How Technology Is Transforming Oncology Care
08/06/2026
Jasmin Hundal, MD, DipABLM, MS, MPH
Jasmin Hundal, MD, DipABLM, MS, MPH, discusses how themes reinforced at the 2026 ASCO Annual Meeting are accelerating the use of digital health technologies that are reshaping oncology practice for advanced practice providers (APPs). She...
Jasmin Hundal, MD, DipABLM, MS, MPH, discusses how themes reinforced at the 2026 ASCO Annual Meeting are accelerating the use of digital health technologies that are reshaping oncology practice for advanced practice providers (APPs). She...
Jasmin Hundal, MD, DipABLM, MS,...
08/06/2026
Oncology Learning Network APP Institute
Jasmin Hundal, MD, DipABLM, MS, MPH
Conference Coverage
AI in Oncology Practice: What APPs Need to Know Now
08/04/2026
Jasmin Hundal, MD, DipABLM, MS, MPH
Following the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Jasmin Hundal, MD, DipABLM, MS, MPH, discussed how artificial intelligence (AI) is becoming an increasingly practical tool for oncology advanced practice...
Following the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Jasmin Hundal, MD, DipABLM, MS, MPH, discussed how artificial intelligence (AI) is becoming an increasingly practical tool for oncology advanced practice...
Following the 2026 American...
08/04/2026
Oncology Learning Network APP Institute
David Spigel, MD, Sarah Cannon Research Institute
Videos
Molecular Assay May Predict Patients With Non-Small Cell Lung Cancer to Benefit From Adjuvant Therapy
06/16/2025
David Spigel, MD
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the...
06/16/2025
Oncology Learning Network APP Institute
Patrick Forde, MBBCh
Videos
Neoadjuvant Nivolumab Plus Chemotherapy Shows Long-Term Survival Benefit Among Patients With Resectable Non-Small Cell Lung Cancer
06/05/2025
Patrick Forde, MD
Patrick Forde, MBBCh, shares insights on the long-term overall survival benefit demonstrated by neoadjuvant nivolumab plus chemotherapy among patients with resectable non-small cell lung cancer, as seen in the CheckMate 816 trial.
Patrick Forde, MBBCh, shares insights on the long-term overall survival benefit demonstrated by neoadjuvant nivolumab plus chemotherapy among patients with resectable non-small cell lung cancer, as seen in the CheckMate 816 trial.
Patrick Forde, MBBCh, shares...
06/05/2025
Oncology Learning Network APP Institute

Experts from across the globe gather to discover and share groundbreaking research among members of the cancer care community who diagnose, treat, and study patients with multiple types of cancer.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use